Innovent and SanegeneBio Announce Initial Dosing of Participant in Early-Stage Trial of IBI3016 (AGT siRNA).

The US FDA extends approval for Jemperli (dostarlimab-gxly) combined with chemotherapy to all adults with advanced or recurrent endometrial cancer. It is the first immunotherapy showing overall survival benefits.

Adaptimmune Gains FDA Accelerated Approval for TECELRA® (afamitresgene autoleucel), the First Engineered Cell Therapy for Solid Tumors in the U.S.

ALX Oncology's Phase 2 ASPEN-06 Trial Shows Evorpacept Enhances Tumor Response in HER2-Positive Gastric Cancer Patients.

Instil Bio and ImmuneOnco reveal partnership for IMM2510, a leading PD-L1xVEGF bispecific antibody, and IMM27M, an advanced anti-CTLA-4 antibody.

Lilly's tirzepatide shows positive results in phase 3 trial for obese adults with heart failure and preserved ejection fraction.

REGENXBIO Inc. announced fresh, encouraging interim results on safety and efficacy from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 in Duchenne muscular dystrophy patients aged 1 to 11 years.

Health Canada has authorized the use of Celltrion's Steqeyma®, a biosimilar of Stelara® (ustekinumab), for managing various persistent inflammatory diseases.

Vaccinex Announces Promising Results from SIGNAL-AD Phase 1b/2 Trial of Pepinemab for Alzheimer's Disease.

Myeloid Therapeutics begins administering MT-303, a new RNA CAR targeting GPC3, in a Phase 1 trial for late-stage hepatocellular carcinoma (HCC).

SanBio Gains Approval for "AKUUGO® Suspension for Intracranial Use" (INN: Vandefitemcel) to Treat Persistent Motor Paralysis from Traumatic Brain Injuries.

The combination therapy was well tolerated, and the safety profile of BNT111 with cemiplimab was consistent with previous trials of BNT111 with anti-PD-(L)1-based treatments.